Pyxis Oncology, Inc. (PYXS) has a consensus analyst rating of Buy, based on 9 analysts covering the stock. Of those, 7 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for PYXS is $6.67, representing a +292.4% upside from the current price of $1.7. Price targets range from a low of $5.00 to a high of $8.00.
